No Data
No Data
No Data
No Data
No Data
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
TipRanksApr 26 00:15
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
TipRanksApr 25 18:30
Gain Therapeutics Shares Rise 8% After Positive Results From Early Trial of Parkinson's Disease Therapy
By Chris Wack Gain Therapeutics shares rose after the company said it saw positive results from an early study of its potential Parkinson's Disease therapy. Shares were up 8% to $3.65 in early tradi
WSJApr 24 21:53
Gain Therapeutics Reports Results From Single Ascending Dose Part Of Phase 1 Clinical Trial Of GT-02287, Novel GCase-Targeting Small Molecule Therapy For GBA1 Parkinson's Disease
GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and tolerability profile and the appropriate range o
BenzingaApr 24 21:26
Oppenheimer Maintains Outperform on Gain Therapeutics, Maintains $9 Price Target
Oppenheimer analyst Hartaj Singh maintains Gain Therapeutics (NASDAQ:GANX) with a Outperform and maintains $9 price target.
BenzingaApr 23 20:21
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
TipRanksApr 23 19:45
No Data
No Data